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Abstract 
 
Background: Glaucoma is the leading cause of irreversible blindness. The last 
decade has seen the emergence of minimally invasive glaucoma surgical procedures, 
with the most recent utilizing implantable devices. The first generation of 
micro-incisional devices has been made of titanium. Since then other materials have 
also been introduced.  In each case, the presence of a permanent foreign body has 
been associated with undesirable wound healing responses characterized by fibroblast 
proliferation and surgical failure. Magnesium alloys have attracted much attention as 
biodegradable implantable materials due to their excellent biodegradable and 
biocompatibility properties. The purpose of this research was to evaluate the in vitro 
biocompatibility and anti-proliferative properties of differently coated magnesium 
alloys in a primary culture of human Tenon’s capsule fibroblasts (HTCFs). The goal 
of the research was to establish a proof of principle for further exploration of this 
novel material as a potential adjunct to glaucoma surgery.  
 
Materials and Methods: Pure magnesium was cut into discs measuring 14.5 mm in 
diameter and 1 mm thick.  These were coated with Hydroxyapatite (HA), Dicalcium 
phosphate dehydrate (DCPD) and Dicalcium phosphate dehydrate + Stearic acid 
(DCPD+SA), respectively. Coated magnesium alloys were immersed in simulated 
aqueous humor to examine the corrosive properties, the released ions, and the 
variation of pH. The primary HTCFs were seeded on DCPD, DCPD+SA and HA 
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disks in 24-well culture and incubated at 37 degrees for 2-7 days.. Glass disks were 
used as control. The MTT and LDH assays were used to determine cellular metabolic 
activity and cytotoxicity during the logarithmic phase of HTCFs, respectively. The 
BrdU assay was used to evaluate cellular proliferation. Western blot was used to 
assess the expression of alpha-smooth muscle actin (α-SMA). 
 
Results: A total of 453 coated magnesium alloy disks were evaluated. Corrosion was 
observed in 67 disks (14.8%). The corrosion rate of HA (12.6%) was lower than other 
two coatings (DCPD 15.9%, DCPD+SA 15.9%, respectively), but the difference was 
not statistically significant different (p=0.851). The immersion test showed that the 
HA coating had better ability to prevent the coating dissolution and corrosion. The 
cellular metabolic activity of different coated magnesium alloys gradually declined 
during the logarithmic phase of HTCFs, and each type of coated magnesium alloy 
demonstrated significant decreased metabolic activity of HTCFs when compared to 
the  control (p<0.001). The cytotoxicity of different coated magnesium alloys 
slightly increased during the logarithmic phase. The group of DCPD+SA showed 
higher cytotoxicity than the other coatings, but it was not statistically significant 
different when compared to the control (p=0.976). Significant inhibition of 
proliferation was observed with the DCPD+SA coating (p=0.47). The expression of 
α-SMA was decreased in the cells when seeded on all of the coated magnesium alloy 
disks. 
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Chemical coatings are able to affect the corrosive properties of magnesium. HA was 
the most resistant to corrosion. No significant difference was found in metabolic 
activity or necrosis at different times during the logarithmic phase of HTCFs. 
DCPD+SA demonstrated a stronger ability to reduce metabolic activity while its 
cytotoxic profile was the same as the titanium and glass controls. In comparison to 
titanium, coated magnesium alloys attenuated HTCFs proliferation. Coated 
magnesium alloys reduced the expression of α-SMA. The expression of α-SMA was 
significantly decreased in cells exposed to the HA coated magnesium  
 
Conclusions: Different chemical coatings on magnesium were able to affect the 
corrosive properties which, in turn, influenced the morphology and function of human 
Tenon’s capsule fibroblasts. These results support the further study of coated 
magnesium for its potential modulatory role in Tenon’s capsule wound healing. 
 
 
Keywords: 
Glaucoma, glaucoma drainage device, fibrosis, tenon’s capsule fibroblasts, 
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Review 
 
A feasibility study of using biodegradable magnesium 
alloy in glaucoma drainage device 
 
Abstract 
Technological advances in glaucoma have challenged the traditional treatment 
paradigm.  Historically, incisional surgery has been used in cases of advanced 
disease and/or uncontrolled intraocular pressures resistant to medical or laser 
interventions. Despite these trends, surgical manipulation of the tissues and 
unpredictability of wound healing continue to result in surgical failure. Magnesium is 
an essential element for the human body and plays a critically important role for 
maintaining the functional and structural integrity of several tissues, including the eye. 
Due to several of its advantageous properties such as 
non-toxicity, biodegradability, and high biological compatibility, magnesium alloy has 
attracted great attention as a novel biomaterial. Biodegradable cardiovascular stents 
made of magnesium alloy have already been introduced into clinical practice. The 
purpose of this review is to determine if bio-absorbable magnesium alloys can be 
utilized as a promising candidate for the development of a new generation of 
glaucoma surgical assistive devices. 
 
Key words: Glaucoma, Tenon’s capsule fibroblasts, fibrosis, Glaucoma drainage 
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devices, Magnesium alloy, Coating, Anti-scarring. 
 
Introduction 
Magnesium is an essential trace element for human life, and also is one of the most 
important regulatory cations involved in several biological processes. Magnesium is 
the second most common cation in the intracellular fluid. Mg2+ plays a crucial role in 
regulating vascular functions and energy metabolism as well as maintaining water and 
electrolyte balance1,2. The level of Mg2+in the serum ranges from 0.8 to 1.2mmol/L, 
with homeostasis being maintained by the kidney and intestine. Hypomagnesemia 
(serum Mg2+<0.8mmol/L) has been suggested to be associated with several disorders, 
such as vascular spasm and arrhythmia. Magnesium deﬁciency may also lead to 
cardiovascular, respiratory, and digestive illnesses, as well as abortion, fetal 
abnormalities and other obstetric diseases3. A large number of studies have shown that 
dietary intake of magnesium can prevent osteoporosis and femoral neck fracture 4-7, 
and help to manage diabetes and coronary artery disease8,9. Serum Mg2+ levels 
exceeding 1.2mmol/L may cause muscular paralysis, respiratory distress and 
hypotension10; however hypermagnesemia is rare due to the efficient excretion of the 
element in the urine11.  
 
Glaucoma is the second most common cause of blindness and the leading cause of 
irreversible worldwide blindness12. Surgery is an important treatment option for 
glaucoma Incisional surgery, with and without glaucoma drainage devices, is a major 
part of the treatment paradigm when medical options cannot be tolerated and/or fail to 
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reach a pressure that halts progression. Long-term complications are often related to 
variability in the wound healing process. Devices used adjunctively in surgical 
glaucoma management represent a foreign body under the conjunctiva, causing 
fibroblast proliferation. This may be due to the persistent effect of inflammatory 
mediators and cytokines at the level of the conjunctival-Tenon-episcleral interface 
resulting in fibrosis and obstruction of the fistula13,14. There continues to be 
significant interest in adjunctive approaches to minimize scarring in the 
subconjunctival space, reducing inflammation, and in slowing or halting the excessive 
fibrotic healing process. 
 
Bleb scarring is a major contributor to increased intraocular pressure (IOP) and 
surgical failure. In order to improve the success rate of glaucoma surgery, various 
intraoperative anti-metabolites have been used to inhibit fibroblast proliferation, such 
as 5-fluorouracil (5-FU) and mitomycinC (MMC). However, these antimitotic agents 
interfere indiscriminately with cellular proliferation, and can contribute to a number 
of postoperative adverse events, including bleb leaks, hypotony, choroidal detachment, 
endophthalmitis, and keratitis15,16. There continues to be a significant need for a safe, 
non-toxic, and effective approach to reduce postoperative scarring and adhesions after 
glaucoma surgery. The relatively recent introduction of bleb-forming micro-invasive 
glaucoma surgery has heightened this interest. 
 
Magnesium alloy is a biodegradable material which possesses many advantageous 
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properties such as high strength, light weight, and high biological compatibility. 
Additionally, magnesium alloy has been shown to be able to reduce irritation and 
inflammatory reactions in the body17-20. We were thus motivated to determine the 
feasibility of developing a magnesium-based bio-absorbable device for modulation of 
wound healing associated with glaucoma surgery. Moreover, the possibility that the 
slow release of Mg2+ by the device could have a local neuroprotective role is an 
intriguing concept worthy of future investigation. 
 
Application of magnesium alloy in modern medicine 
The application of magnesium alloy as a bio-absorbable material in clinical practice 
can be traced back to the early 1900s. The first use of magnesium was reported by 
Lambotte et al. in 1907, who utilized a plate of pure magnesium with gold-plated steel 
nails to treat a fracture involving the bones of the lower leg.  The initial attempt 
failed as the pure magnesium plate corroded too rapidly in vivo, disintegrating only 
eight days after surgery and producing a large amount of gas under the skin21,22. In 
1938, McBride et al. developed magnesium alloy fixtures which successfully treated 
20 cases of fracture without any significant adverse effects, and the fixtures were 
completely absorbed three months after surgery 23. In 1944, Troitskii et al. applied 
cadmium magnesium alloy as an internal fixation device to secure the bones of 34 
consecutive fracture patients. They observed that the fixture could maintain the 
mechanical integrity up to two months, and it was completely absorbed after 10-12 
months. Nine cases were unsuccessful, and these failures were attributed to infection. 
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A hard callous was found around the fracture site with no increase in serum levels of 
magnesium and no obvious inflammatory reactions to the implantin all 34 patients 
who were studied23. Znamenski et al. reported similar results in 1945, where 
magnesium alloy containing 10% aluminum (Al) was used to treat two patients with 
gunshot wounds. The magnesium implant and nails were completely absorbed after 
4-6 weeks23. These early reports demonstrated that magnesium alloy was a non-toxic 
biomaterial, and it had the ability to promote bone healing. However, due to its 
characteristics of hydrogen emission and low corrosion resistance in the electrolytic 
and aqueous environments of the physiological system, biomaterial research on 
magnesium alloy was suspended. Thereafter, stainless steel materials were widely 
applied in bone internal fixation devices. Until recent years, with the use of advanced 
techniques, more complicated alloy compositions have been introduced. 
Advancements in corrosion protection technologies have effectively reduced the 
production of hydrogen gas. It is for these reasons that interest in the medical use of 
magnesium alloys has once again increased.23.   
 
Numerous in vitro and in vivo studies have focused on the use of magnesium alloys in 
internal fixation devices for fracture repairs. The corrosion resistance of different 
types of coated magnesium alloys has been studied in cytological and animal 
experiments to determine the reduction in hydrogen evolution and tissue compatibility 
24,25. In vitro experiments confirmed that there were minimal cytotoxicity and cell 
apoptosis when fibroblasts and osteoblasts were exposed to various coated 
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magnesium alloys25. In vivo experiments found that Mg2+ could enhance bone 
formation during the degradation process of the implant, and no inflammation was 
observed26,27. F.Witte et al. successfully implanted magnesium alloy stents into the 
femur of rabbits, and the magnesium implants substantially degraded after three 
months. Their study also showed that the degradation process of the magnesium alloy 
stents could promote trabecular bone formation and resorption, without any 
significant harm to their neighboring tissues. They concluded that even fast-degrading 
magnesium alloy stents could show favourable biocompatibility thus establishing a 
more convincing potential role, in musculoskeletal surgery28,29. In addition, F.Witte et 
al. also carried out an in vitro experiment to investigate the properties of a metallic 
matrix composite made of magnesium alloy AZ91 as a matrix with hydroxyapatite 
(HA) particles as reinforcements. The results revealed that the HA particles could 
stabilize the corrosion rate of the magnesium alloy, and this biodegradable metallic 
matrix composite HA was a cyto-compatible biomaterial with adjustable mechanical 
and corrosive properties30. Okazaki M et al. developed a novel material containing 
magnesium, calcium, and phosphate for use as oral implants. They found that 
magnesium increased the metabolic rate of osteoblasts31. Zreiqat et al. found that the 
protein levels were significantly higher in human bone-derived cells cultured on 
[Mg]-Al2O3 (alumina doped with magnesium ions) compared with those grown on 
Al2O3 alone
32. Hunt Jet al. reported that the magnesium-coated Ti-6Al-4v implant 
could activate bone cell signal transduction and hence improve protein synthesis and 
accelerate bone formation33. The mechanical and degradation properties of 
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magnesium have been used to develop novel cardiovascular stents, so as to maintain 
the endothelial function of coronary arteries and to reduce the risk of coronary 
ischemia and occlusion34-37. Based on a large number of clinical trials38,39, magnesium 
coronary stents have been introduced into clinical practice40. 
 
The important roles of Mg2+ in the eye 
Mg2+ is important for maintaining the structural and functional integrity of several 
vital ocular tissues such as the cornea; lens and retina. The concentration of 
magnesium in aqueous humor is 2.97 ± 0.75 mg/ 100 ml. The magnesium levels in the 
lens are far higher than those in the anterior chamber and vitreous body. The 
concentration in the lens periphery is four times greater than the axial regions41. Mg2+ 
plays an extremely important role in maintaining retinal function. The reason for this 
is because magnesium acts as a co-factor involved in the catalytic function of more 
than 350 enzymes in the body and regulates neuro-excitability. Membrane associated 
ATPase functions that are crucial in regulating the intracellular ionic environment, are 
also magnesium-dependent. As a result, a reduced level of Mg2+may affect the 
functions of Na+/K+ ATPase and calcium dependent ATPase, causing an increase in 
the intracellular concentrations of calcium and sodium as well as a decrease in the 
potassium42 concentration. Such ionic imbalances induced by magnesium deficiency 
may contribute to the pathogenesis of many eye disorders, such as cataract, corneal, 
conjunctival, choroidal and retinal diseases43,44. 
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Maintenance of corneal structure and function  
Mg2+ is one of the most important cations in the cornea as it is involved in the 
metabolism and maintenance of corneal transparency45. As early as 1920, Kirkpatrick 
et al. reported the use of magnesium sulfate in the treatment of keratitis, conjunctivitis, 
and corneal ulceration46. In 1985, Bachman and Wilson performed an animal 
experiment and found that the epithelial surface of the excised rabbit cornea was 
maintained best with a buffered solution containing Mg2+, K+, and Ca2+ 47. Hogan et al. 
reported that Mg2+ loss in the corneal stroma was associated with corneal edema48. In 
2001, Gong et al. investigated the effect of magnesium deficiency on the cornea in 
rats that were fed a low magnesium diet for 3 weeks. Their findings revealed that 
magnesium deficiency affected the structural and functional integrity of the cornea49. 
 
Keratoconus is defined as a progressive eye disease which causes thinning and 
fragmentation of membranes, degenerated cells and collagen fibers, swelling of the 
mitochondria, and biochemical abnormalities in protein synthesis and expansion of 
central area of the cornea. Thalasselis et al. reported that hypomagnesemia was 
commonly seen in the serum samples of keratoconus patients, and magnesium 
deficiency could pathologically affect the integrity of the cornea50. Prior studies also 
showed that magnesium deficiency was associated with a reduced number of 
microvilli and their irregular arrangement. Vesicular degeneration and swelling of the 
mitochondria were observed in the cytoplasm of epithelial cells, resulting in abnormal 
apoptosis of thesecells51,52. Magnesium deficiency was also associated with rupture 
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and fragmentation of the Bowman’s layer, which may be an early change leading to 
keratoconus53,54. 
 
Supporting lens metabolism and preventing cataract  
Cataract is the most common cause of blindness worldwide. It is characterized by 
progressive lenticular opacities. It is known that cataractous lenses have an abnormal 
intracellular ionic environment with lower concentrations of potassium and 
magnesium and higher concentrations of sodium and calcium relative to the cytosol of 
most cells. The lens membrane has increased permeability in the presence of a 
cataract55. Studies have explored he relationship between magnesium deficiency and 
cataract. These studies have shown that the alterations in lenticular redox status and 
ionic imbalances form the basis of the relationship between magnesium deficiency 
and cataract. It is believed that Mg2+ plays an important role not only in maintaining a 
low lenticular Ca2+ and Na2+ concentration but also in preserving the lens redox status, 
which has been shown to reduce lenticular oxidative stress56,57. Nagaiet al. reported 
that the incidence of cataract was significantly lower in Shumiya rats fed 200mg/L 
magnesium compared to controls. It was noted that the intracellular Ca2+ level of the 
lenses was also significantly lower58. Based on these findings, they concluded that an 
appropriate supplementation of magnesium could delay cataract genesis, probably by 
inhibiting the increase in Ca2+ levels in the lens59. After a thorough literature review, 
Agarwal et al. concluded that magnesium supplementation might be of therapeutic 
value in preventing the onset and progression of cataract60. 
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Oxidative stress is another important contributor to the pathogenesis of cataract. It has 
been shown in many studies that nitric oxide (NO) could be a risk factor in cataract 
formation61. NO production via inducible nitric oxide synthase (iNOS) causes an 
oxidative stress response in the lens62. Mg2+ has been shown to prevent the increase of 
NO in the lens which provides protection by inhibiting the nitrosylation of gap 
junctional proteins and maintaining membrane permeability63. It is also known to 
block iNOS expression and reduce the oxidative stress response. A cytological 
experiment found that the expression of iNOS was 6 times higher in the lens epithelial 
cells cultured in the magnesium-deficient medium compared to those cultured in the 
magnesium-supplemented medium. In addition, Mg2+ was shown to regulate Ca2+ 
ATPase thus modulating the concentration of Ca2+ in the lens. 
 
Both magnesium deficiency and excessive NO production have been shown to 
decrease ATP levels58. The reduction in ATP levels affects the membrane-associated 
Ca2+ ATPase and Na+/K+ ATPase, causing ionic imbalance in the lens. Interestingly, 
the decreased ATP levels in turn may have inhibitory effects on the expression of 
iNOS64. Therefore, it has been speculated that magnesium deficiency may cause an 
acceleration of the progression of lens opacification (Figure 1). 
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Figure 1. Magnesium deficiency contributes to the pathogenesis of cataract 
development.  
 
Glaucomatous neuroprotection  
Elevated intraocular pressure (IOP) is not the sole risk factor for chronic 
glaucomatous neuropathy. In fact, the search for putative non-IOP dependent factors 
continues to be of significant interest. Vasomotor dysfunction has also been suggested 
to contribute to optic neuropathy, by mediating abnormal hemodynamics and 
oxidative stress65. In an epidemiological study, Bonomi et al. reported that reduced 
diastolic perfusion pressure could be an important risk factor for primary open-angle 
glaucoma66. Leske et al. reported an association between cardiovascular disease and 
glaucoma which suggested a vascular role in glaucomatous progression67. It has been 
well-established that Mg2+ can function as a physiological Ca2+ channel blocker which, 
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in turn, prevents ischemia and provides protection to the optic nerve. A large number 
of studies concerning ocular blood flow and oxidative stress response have confirmed 
that Mg2+ may regulate the current strength and in activation process of Ca2+ 
channels68,69. Even small changes in extracellular Mg2+ levels may have significant 
effects on vascular tone. Mg2+ has been shown to have a direct vasodilatory effect70-72 
while magnesium deficiency has been shown to increase intracellular Ca2+levels 
leading to vasoconstriction73,74. Moreover, as Mg2+ regulates Na+/ K+ ATPase, 
magnesium deficiency is associated with reduced activity of Na+/ K+ ATPase and 
increased intracellular Na+ and Cl- levels causing cellular swelling and apoptosis of 
retinal ganglion cells (RGCs) 75.  
 
Other studies have demonstrated an association between plasma endothelin-1 (ET-1) 
levels and normal tension glaucoma (NTG).  Patients with NTG in the initial stage of 
visual field loss demonstrated higher plasma ET-1 levels than those with moderate 
visual field damage76. An increase in extracellular Mg2+ levels inhibits ET-1, which 
may induce constriction and vasospasm of the ciliary arteries, with reduced blood 
supply to the optic nerve. Furthermore, ET-1 may affect the functions of axons and 
astrocytes, and accelerate the apoptosis of RGCs77. It has been suggested that the 
favorable effects of magnesium on the visual field may be attributed to ET-1inhibition, 
suppressing vasoconstriction, improving the ocular blood flow, and preventing 
glaucomatous neuropathy43.  
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The ion channel of the N-methyl-D-aspartate (NMDA) receptor is calcium dependent 
and subject to voltage-dependent regulation by Mg2+. Mg2+ can regulate the 
glutamate-gated ion channel which, in turn, has been shown to prevent excitotoxicity 
and cell apoptosis78-81. In the presence of a magnesium deficiency, the toxic effects of 
glutamate on RGCs are mediated by the over stimulation of NMDA receptors, leading 
to glutamate excitotoxicity and loss of RGCs in glaucoma patients. Lambuk et al. 
reported that intravitreal Mg2+ could prevent retinal and optic nerve damage induced 
by NMDA82. Moreover, intracellular accumulation of Ca2+associated with magnesium 
deficiency has been associated with the production of free radicals83,84. 
 
Magnesium deficiency directly increases the expression of iNOS. Lower levels of 
Mg2+ have been associated with vasospasm and retinal ischemia which also enhance 
the expression of iNOS85, and produce large amounts of free radicals86. Numerous 
studies have shown that Mg2+ plays a neuroprotective role in inhibiting the elevated 
iNOS activity of neurons in retinal ischemia87,88. 
 
In a study by Gaspar et al., 10 glaucoma patients including 6 with primary open-angle 
glaucoma (POAG) and 4 with NTG were administered magnesium 121.5mg, twice a 
day for one month. Results showed that magnesium significantly increased the ocular 
blood flow and improved the peripheral circulation, exerting a beneficial effect on the 
visual field in glaucoma patients with vasospasm89. Aydin et al. also reported that in15 
NTG patients who received 300 mg oral magnesium citrate for a month, an 
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improvement in the visual field was observed, but the ocular blood flow remained 
unchanged. They speculated that mechanisms other than increased ocular blood flow 
may be responsible for the improvement in the visual field when given oral 
magnesium therapy90. Based on these findings, it was suggested that Mg2+may play an 
important role in optic neuroprotection in patients with glaucoma (Figure 2). 
 
 
Figure 2. Magnesium deficiency contributes to the pathogenesis of glaucomatous 
neuropathy. 
 
The history and prospects of using magnesium materials in glaucoma drainage 
surgery 
Due to the unique properties of magnesium and its satisfactory bio-compatibility, the 
use of the pure materials was considered as an implant for the treatment of glaucoma 
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in the middle of the 20th century. In 1940, Troncoso utilized pure magnesium 
implants to increase the aqueous outflow in the treatment of glaucoma91. Five years 
later, Boshoff used this technique to treat a patient with neovascular glaucoma who 
refused enucleation, Twelve hours after operation, the patient’s whole anterior 
chamber was filled with gas and the IOP was significantly increased, resulting in 
severe pain. The pressure of the gas was relieved by venting with a thin hypodermic 
needle. The IOP normalized on the sixth postoperative day, but huge bubbles were 
still found in the anterior chamber and the conjunctiva, which disappeared on the 
tenth day. Interestingly, before the operation the cornea was opaque at an IOP of 54 
mmHg, but it became absolutely clear when the anterior chamber was full of gas, 
despite the elevated IOP which varied from 49 to 55 mmHg. The postoperative IOP 
was controlled at 1-4 months after surgery, but elevated to 45mmHg again at the fifth 
month. Gonioscopy revealed complete circumferential iridocorneal synechiae. Coarse 
pigment granules were observed in the dependent part of the angle. Eventually, the 
eye was removed. Pathological examination revealed a closed filter channel and 
massive fibroblast proliferation around the incision92. 
 
These experiences indicated that pure magnesium had significant adverse effects due 
to the excessive corrosion when in contact with body fluids due to hydrogen gas 
emission. This limited its potential therapeutic benefits when used as a pure, uncoated 
material.  Since then, advancements in the area of coating technology have allowed 
the synthesis of novel coated magnesium alloys with optimized compositions 
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(containing aluminum, zinc, manganese, calcium, praseodymium, or neodymium) 
allowing control over the corrosive properties. Coated magnesium alloys have shown 
significant promise as effective biodegradable materials in vivo.  
 
During the last 15 years, biodegradable metallic stents have been developed and 
investigated as alternatives for the currently-used permanent cardiovascular stents93-95. 
Traditional cardiovascular stents have significant drawbacks including irritation and 
damage to the vascular endothelium, leading to stenosis and blockage 96-99. In order to 
solve these problems, absorbable magnesium materials have shown success. In vitro 
studies have demonstrated that magnesium cardiovascular stents can maintain the 
integrity and function of endothelial cells, as well as reduce inflammation and 
fibroblast proliferation. In these studies, stents could be fully absorbed within 2-4 
months with few complications observed during a two years of follow-up period37,39. 
Subsequently, a large number of clinical trials were conducted37,38. In 2007, a 
prospective multi-center trial in patients with coronary heart disease was published in 
the Lancet, which showed that biodegradable magnesium stents achieved an 
immediate angiographic result similar to the result of traditional metal stents and was 
safely degraded after 4 months 100.  
 
The introduction of magnesium cardiovascular stents has led to interest in how their 
use can be expanded into other areas of the body. In particular, their potential utility as 
an adjunctive device in glaucoma surgery is of high interest due to recent 
  xxx 
developments in the area of micro-invasive glaucoma procedures. The excellent 
biocompatibility and bio-degradability have the potential to allow magnesium alloy 
devices to effectively decrease postoperative irritation, reduce scar formation, 
improve the success rate of glaucoma surgery, and minimize the long-term effects of 
permanent implants which tend to produce local complications related to tissue 
compression. The liberation of Mg2+ cations during the natural degradation process 
has many potential beneficial effects on the cornea, lens, retina, choroid, and optic 
nerve. 
 
In conclusion, bio-absorbable coated magnesium alloys may be a very promising 
candidate for the development of a new generation of glaucoma drainage devices. 
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Chapter 1 
Introduction 
1.1 Glaucoma 
The glaucoma is a group of diseases that have in common a characteristic optic 
neuropathy with associated visual field loss for which elevated intraocular pressure 
(IOP) is one of the primary risk factors.  
 
Most patients with early glaucoma are asymptomatic. The great majority of patients 
lack pain, ocular inflammation, or halos.  Significant peripheral vision can be lost 
before the patient notices visual disability. If glaucoma is detected early and treated 
medically or surgically, blindness can be prevented. 
 
1.1.1 Epidemiology of glaucoma 
The World Health Organization ranks glaucoma as the second most common cause of 
blindness, and as the leading cause of irreversible blindness worldwide101,102. Since 
2010 there are about 60.5 million patients who suffered from primary open angle 
glaucoma (POAG) and primary angle-closure glaucoma (PACG) all over the world. 
The amount will become 79.6 million considerably, and it has been estimated that 
over 5.9 million people worldwide will be bilaterally blind with open-angle glaucoma 
by 2020103. Two main types of glaucoma can be classified according to etiology: 
primary angle closure glaucoma and primary open-angle glaucoma. The highest 
prevalence of open-angle glaucoma occurs in Africans, and the highest prevalence of 
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angle-closure glaucoma occurs in the Inuit. 
 
1.1.2 Aqueous Humor and Outflow 
Elevated IOP is a well-known causative risk factor for both the development and 
progression of glaucoma. Within the eye is a mechanism for the continuous 
production and drainage of fluid. This fluid is called aqueous humor (AH). Intraocular 
pressure is regulated by aqueous humor production in the ciliary body and drainage 
from the eye occurs by way of the trabecular meshwork (TM) and uveoscleral 
pathways. 
 
Aqueous humour is secreted into the posterior chamber by the ciliary body, 
specifically the non-pigmented epithelium of the ciliary body. It flows from the ciliary 
processes into the posterior chamber, bounded posteriorly by the lens and the zonules 
of Zinn, and anteriorly by the iris, to escape through the pupil into the anterior 
chamber, and then to drain out of the eye via the trabecular meshwork. From here, it 
drains into Schlemm's canal by one of two ways: directly, via aqueous vein to the 
episcleral vein, or indirectly, through collector channels to the episcleral vein by 
intrascleral plexus into the veins of the orbit and eventually general blood circulation. 
Because of some resistance to the flow of aqueous through the trabeculum and 
Schlemm’s canal, presuure is created in the eye. 
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Figure 1.1.2 The trabecular meshwork outflow pathways.  
 
1.1.3 Pathogenesis 
Although the pathogenesis of glaucoma is not fully understood, the level of 
intraocular pressure is related to retinal ganglion cell death. Intraocular pressure can 
cause mechanical stress and strain on the posterior structures of the eye, notably the 
lamina cribrosa and adjacent tissues. In addition, elevated intraocular pressure is not 
the only risk factor for chronic glaucomatous neuropathy, In fact, the search for 
putative non-IOP dependent factors continues to be of significant interest. Vasomotor 
dysfunction has also been suggested to contribute to optic neuropathy, by mediating 
abnormal hemodynamics and oxidative stress65. 
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1.2 Glaucoma treatment options 
Slowing disease progression and preservation of quality of life are the main goals for 
glaucoma treatment. Current management guidelines from the American Academy of 
Ophthalmology Preferred Practice Patterns recommend lowering the intraocular 
pressure toward a target level, which is a value or range of values at whichthe rate of 
disease progression will be slowed sufficiently to avoid functional impairment from 
the disease104. The target intraocular pressure should be achieved with the fewest 
medications and/or surgeries, and with a minimum of adverse effects. When glaucoma 
is no longer controlled by maximally tolerated medical therapy or laser 
trabeculoplasty, incisional ab externo filtering surgery has been the traditional next 
step in the therapeutic management.  
1.2.1 Filtration surgery 
Filtration surgery still plays a mainstream role in the treatment of glaucoma despite 
the fact its development dates back to the 19th century. Trabeculectomy (TRAB) is 
still the most popular surgical intervention in patients who aﬀected by primary 
glaucoma, and is the most commonly performed incisional surgical procedure to 
lower intraocular pressure. The trabeculectomy was introduced almost 50 years ago 
with very few modifications since that time.  Trabeculectomy is generally 
recommended for patients with glaucoma that continues to progress despite use of 
medications and/or laser treatments. It consists of excision of a small portion of the 
trabecular meshwork tissue to provide a drainage route for aqueous humor from 
within the eye to underneath the conjunctiva where it is absorbed. However, the 
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trabeculectomy can contribute to a number of adverse effects, such as: scaring, 
bleeding, infection, malignant glaucoma. Therefore, a new class of glaucoma 
procedures, termed microinvasive glaucoma surgery, has emerged, which aims to fill 
the gap between conservative medical management and more invasive surgery.  
 
1.2.2 Glaucoma drainage devices 
Although the procedure itself has not changed much in the last 50 years, chemical 
agents that modulate the fibroblastic response to the surgery have been more recently 
introduced.  These agents, known as 5-fluorouracil and mitomycin C have effects at 
the cellular level in blunting the would healing response.  In addition, 
trabeculectomy is not the only choice of ab externo glaucoma surgery . These 
procedures have been augmented, traditionally in more advanced cases, with macro- 
glaucoma drainage devices and implantations. Glaucoma drainage devices are 
designed to divert aqueous humor from the anterior chamber to an external reservoir, 
where a fibrous capsule forms about 4-6 weeks after surgery and regulates flow. 
Lowering IOP can be achieved by increasing aqueous humour drainage through this 
artiﬁcial route. These devices have shown success in controlling intraocular pressure 
(IOP) in eyes with previously failed trabeculectomy and in eyes with insufficient 
conjunctiva because of scarring from prior surgical procedures or injuries. They also 
have demonstrated success in complicated glaucomas, such as uveitic glaucoma, 
neovascular glaucoma, and pediatric and developmental glaucomas, among others. 
Therefore, glaucoma drainage devices are being used increasingly in glaucoma 
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surgery. Currently, the glaucoma drainage devices are available in different materials.  
These “macro” ab externo adjunctive devices provided a basis for the emergence 
ofthe first generation of micro-incisional devices.  The latter have been made of 
various materials with one of the first being titanium.   
 
1.3 Fibrosis 
1.3.1 Anti-fibrotic agents 
In general, filtering procedures such as trabeculectomy or placement of 
subconjunctival drainage implants, aim at allowing aqueous humor to leave the 
anterior chamber through a novel transscleral route towards the subconjunctival space. 
Scarring is a major cause of increased intraocular pressures and surgical failure. In 
order to prevent bleb scarring and obstruction of the fistula, the inhibition of cellular 
proliferation and inﬂammation is both necessary and desirable after surgery for 
glaucoma. Currently, various substances have been used for the modulation of wound 
healing in filtering glaucoma surgery. In ﬁltering glaucoma surgery, the most 
frequently used anti-fibrotic agents are mitomycinC (MMC), and 5-ﬂuorouracil 
(5-FU). These anti-fibrotic agents improve the success rate for long-term intraocular 
pressure (IOP) control and reduce the risk of bleb failure105,106. but their use is 
associated with an increased complication rate including thin-walled blebs107, 
hypotony108, wound leakage109 and infection110. Until now, no satisfactory methods 
have been developed to resolve this issue. 
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Figure 1.3.1 Clinical presentation of filtering blebs.  
(A) Unscarred diffuse filtering bleb 12 months following trabeculectomy. (B) Scarring filtering bleb 
with beginning encapsulation (arrows) and enhanced vascularity, 6 weeks following trabeculectomy. G. 
Schlunck et al. / Experimental Eye Research 142 (2016) 76-82.  
 
1.3.2 Permanent foreign body under tenos’s capsule stimulates fibrosis 
Currently, permanent and inert metals like Titanium alloy, Polypropylene, and 
Silicone are the most common materials used in adjunctive glaucoma surgical 
devices. . However, it has been found that these materials can be associated with 
long-term complications. One reason is that the presence of the permanent foreign 
body induces inflammation stimulation under the tenon’s capsule. The initial process 
of inflammatory is characterized by the increasing of monocytes and lymphocytes 
with the early proliferation of connective tenon’s capsule tissue111. Thisis a main risk 
factor cause fibroblast proliferation112-114 and fibrosis115,116. 
 
Inflammatory responses of organisms against foreign body are a natural defense 
process, which, in turn, is one of the greatest challenges in the development of 
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permanent implantable devices117,118. The foreign body may be associated with 
subconjunctival inflammation due to toxic and allergic responses. The inflammatory 
phase is characterized by the activation of the innate immune system and the release 
of inflammatory cytokines. Chronic inflammation is an established risk factor for 
fibrosis due to the release of mediators such as interleukin-1（IL-1） and tumor 
necrosis factor-alpha （TNF-α）which lead to increased tissue levels of TGF-β. 
Chronic inflammatory reactions associated with the foreign body can accelerate 
wound scarring, resulting in failure of the glaucoma surgery. It is for these reasons 
that higher surgical success rates may occur if the inhibitory substances remain in 
intimate contact with the tissue whose proliferation should be prevented, while 
supporting the well-being of the tissues whose integrity is necessary to prevent 
complications and promote healthy function.  Ideally, the implantable material would 
do its job in the acute phases of wound healing and then auto-degrade to limit the 
potential for chronic responses to a foreign body. 
 
Figure 1.3.2 Conjunctival scarring following filtering glaucoma surgery.  
Fibroblasts (orange) proliferate and differentiate into myofibroblasts (red). Drivers of fibrosis: (1) 
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sutures, (2) blood, vessel-derived cells, cytokines and growth factors, (3) aqueous humor-derived 
growth factors, (4) shear force stimulation by interstitial fluid flow, (5) signaling molecules released 
from ECM storage sites, (6) myofibroblast transdifferentiation leading to matrix deposition and tissue 
compaction. G. Schlunck et al. / Experimental Eye Research 142 (2016) 76-82 
 
1.4 Magnesium 
1.4.1 The important roles of Mg2+ 
Magnesium is an essential trace element for human life, and is one of the most 
important regulatory cations involved in several biological processes. Magnesium is 
the most common divalent cation in the intracellular fluid, and plays an important role 
in regulating vascular functions and energy metabolism, as well as maintaining water 
and electrolyte balance. Mg2+ is important for maintaining the structural and 
functional integrity of several vital ocular tissues such as the cornea; lens and retina119. 
Magnesium deficiency may contribute to the pathogenesis of many eye disorders, 
including, cataract, conjunctival diseases, corneal diseases, choroidal diseases, and 
retinal diseases. Magnesium is a nature’s calcium blocker120, increase blood flow to 
tissues through endothelin-1 and endothelial nitric oxide pathways121. As well as, 
magnesium has been shown neuroprotective role to glaucoma patients122,123 that 
prevent oxidative stress and apoptosis124.   
 
1.4.2 Magnesium alloys  
Magnesium alloy has a variety of advantageous characteristics which include:   
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biodegradable, non-toxic, high strength, light weight, and high biological 
compatibility125. Due to the unique properties and satisfactory biocompatibility the 
application of magnesium alloy as a bio-absorbable material in clinical practice can be 
traced back to the early 1900s for treatment of bone fracture patients, which 
demonstrated it was a non-toxic biomaterial21-23. Magnesium alloy also has been 
considered as a potentially appropriate biomaterial for glaucoma drainage devices. 
Various studies have found that magnesium alloys are biologically safe and have 
demonstrated  positive biological reactions in ocular tissue126. In comparison with 
polymers, the degradation products of the alloys which includes magnesium ions are 
needed in the human body for physiological functions, with consumption lying in the 
range 250–500mg day. About 20g of Mg is always present in the average 70kg human 
body127. 
 
1.4.3 Coating techniques improve corrosive property  
Magnesium as a pure metal has poor corrosion resistance, which has been  a major 
obstacle to their application as a human implantable device.  If corrosion is rapid and 
not homogenous, it limits its potential in vivo applications. Another issue is the 
formation of hydrogen gas during corrosion: if evolution of the gas is too rapid it 
cannot be absorbed and a balloon effect takes place. Fortunately, in recent years, the 
most attention in the magnesium alloy field has been the study of coatings or surface 
modification to slow the degradation rates of various Mg alloys. This has caused a 
renewed interest in the use of magnesium as a surgical adjunctive device. There are a 
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large number of possible coating technologies for Mg biomaterials, including 
anodisation, metal–metal coatings, plasma spray, chemical vapour deposition, pulsed 
laser deposition, ion beam assisted deposition, solution coatings, calcium phosphate 
(CaP) deposition achieved by various means and the well known methods of 
electrodeposition and conversion coating. The CaP coatings have garnered the 
majority of attention due to their intrinsic biocompatibility128-130, due to the formation 
is similar to the mineral phase of bone, including hydroxyapatite (HA), dicalcium 
phosphate dehydrate (DCPD) and dicalcium phosphate dehydrate +Stearic acid 
(DCPD+SA).  
 
Nowadays, the advancement techniques have fabricated a new generation of 
magnesium alloys, especially the development of coating technique which effectively 
reduced the production of gas and rapid corrosion in the body. The coated magnesium 
alloys have been used to develop novel cardiovascular stents resulting in a number of 
clinic trials37-39.  It is for these reasons that we were interested in exploring the 
feasibility of coated magnesium devices as a potential surgical adjunct to glaucoma 
surgery. 
 
1.5 Hypothesis and Objectives 
The preliminary data showed that coated magnesium alloy may reduce metabolic 
activity and potentially inhibit human tenon’s capsule fibroblasts（HTCFs）cells 
growth and proliferation. The results indicated that different coated magnesium alloys 
had different inhibitory ability on HTCFs proliferation, and this effect may be 
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associated with the capacity of blocking cell cycle. 
 
1.5.1 Hypothesis 
Bio-degradable coated magnesium alloys will inhibit cellular proliferation and reduce 
myofibroblast activity in a primary culture of human Tenon’s capsule fibroblasts. 
 
1.5.2 Objectives 
The purpose of this study was to evaluate the biocompatibility and anti-proliferative 
potential of different coated magnesium alloys on the activity of human Tenon’s 
capsule fibroblasts in primary cell culture.  
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Chapter 2 
Primary cell culture and sample preparations 
2.1 Materials and methods 
2.1.1 Primary HTCFs culture 
The tenon’s capsule samples were obtained from 32 glaucoma patients without a past 
history of ocular surgery. The study has been approved by the Research Ethics 
Committee of St. Joseph’s Hospital, Western University, London, Canada. All the 
patients provided informed consent, and the study was conducted in accordance with 
the Declaration of Helsinki. The capsule samples were excised during the surgery, and 
cultured in a 60 mm dish. The culture medium, consisting of Dulbecco’s modified 
Eagle’s medium (DMEM, Gbico, USA) supplemented with 10% fetal bovine serum 
(FBS, USA) and 1% penicilin/streptomycin (Gbico, USA), was changed every 2-3 
days and the cells were allowed to reach 80% confluence. Subsequently, the cells 
were disaggregated with 0.25% trypsin and 0.02% EDTA at 37oC for 5 min. And then, 
the HTCFs cells were transferred to 25 cm2 flasks (BD Falcon, BD Biosciences, 
Broendby, Denmark), which were placed at 37oC in 5% CO2 incubator for subculture. 
The cells were seeded in a 24-well plate when they reached 80% confluence. 
 
2.1.2 Assessment of morphology 
The cells were analyzed 2 days after seeding. Cell counting was performed by 
fluorescence microscopy (Axio Observer. Z1; Carl Zeiss, Germany) using Heochst 
dye (Molecular Probes, Carlsbad, CA, USA) to visualize the nuclei. After 10 minutes 
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of incubation with the fluorescent dye, the cells were fixed with 4% buffered 
formaldehyde in phosphate buffered saline (PBS) for 10 minutes, and then 
permeabilized with 0.1% Triton-X 100 in PBS for 5 minutes. Thereafter, the samples 
were rinsed with PBS, stained with a 1:100 dilution of monoclonal mouse 
anti-vimentin and 1:500 monoclonal rabbit anti-keratin, and then left overnight at 9oC. 
After a PBS rinse, the samples were incubated in a 1:625 dilution of anti-mouse Alexa 
Fluor 488-conjugated goat anti-mouse IgG for 1 hour at room temperature. For double 
labeling, the samples were also incubated in a 1:500 dilution of Alexa Fluor 
568-conjugated donkey anti-rabbit IgG for 1 hour at room temperature. Finally, the 
samples were rinsed twice with PBS and kept in PBS at 4oC until the observation 
time.Image sampling, cellular morphology assessment and cell counting were 
performed using custom-written routines for the AxioVision rel.4.7 software (Carl 
Zeiss). 
 
2.1.3 Fabrication of differently coated magnesium alloys  
Magnesium alloys with a purity of 99.99% were obtained from the National 
Engineering Research Centre for Magnesium Alloys, Chongqing University, China. 
The pure magnesium was cut into disks with 14.5 mm in diameter and 1 mm in 
thickness after pretreatment at 550oC for 24 hours of annealing. The surface of the 
disks was polished using 320-800# abrasive paper. All of the disks were ultrasonically 
cleaned in acetone, air dried and weighed. Thereafter, the magnesium disks were 
coated with hydroxyapatite (HA, Figure 2.1.3.A), dicalcium phosphate dihydrate 
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(CaHPO4·2H2O, DCPD, Figure 2.1.3.B), and DCPD + stearic acid (DCPD + SA, 
Figure 2.1.3.C), respectively. The HA coating was composed of 0.25 mol/L 
ethylenediaminetetracetic acid calcium disodium salt hydrate (Ca-EDTA) and 0.25 
mol/L potassium dihydrogenphosphate (KH2PO4), and the thickness of coating was 
2um. The DCPD coating was composed of 3.1% sodium hydrogen phosphate 
(Na2HPO4) and 5.3% calcium nitrate (Ca(NO3)2). The HA and DCPD coatings formed 
with chemical bond of calcium phosphate and magnesium matrix. The thickness of 
DCPD coating was 3um. The DCPD + SA coating was treated based on the 
DCPD-coated magnesium disks with the addition of stearic acid. The combination of 
SA depends on hydrogen bond and physisorption. The thickness of DCPD+SA 
coating was 4um. Finally, all of the coated magnesium disks were ultrasonically 
cleaned. 
 
(a) 
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(b) 
 
                                         (c) 
Figure 2.1.3 Scanning electron microscope (SEM) images of different magnesium coatings. 
(A) SEM morphology of HA; (B) SEM morphology of DCPD; (C) SEM morphology of DCPD + 
SA. 
 
2.1.4 Magnesium sample preparation 
The coated magnesium samples were immersed in 70% ethanol for 10 minutes, and 
rinsed twice with distilled water, and then dried under UV light. The samples were 
introduced into a separate 24-well plate (BD Falcon, BD Biosciences, Broendby, 
Denmark), with 5 x 104 primary HTCF cells per well (Invitrogen Countess™). The 
glass and titanium disks were used as controls (Figure 2.1.4).   
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During the experiments, if a coated magnesium disk emitted hydrogen gas, the gas 
would elevate the disk. We defined this phenomenon as corrosion, recorded it and did 
not use such disks for our experiments.  
 
Figue.2.1.4 Different sample groups for experiments. 
 
2.1.5 Statistical analysis 
The corrosion rate of differently coated magnesium alloys were compared using 
chi-square test. The corrosion susceptibility of different coatings from day 2 to day 7 
was compared using two-way analysis of variance (ANOVA). Statistical significance 
was accepted at P < 0.05. All analyses were performed using SPSS 24.0 software. 
 
2.2 Results 
2.2.1 Cell morphological observation and identification of HTCFs by 
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immunofluorescence staining. 
The cells migrated out from the tissue after 7-10 days of adherent culture. 
Microscopically, the cells exhibited a fusiform appearance with clear outline, and the 
cellular plasma was abundant, bright, and uniform-sized. The cells were arranged in 
fasciculus or swirling patterns. No differences were observed between the recovered 
cells and those before cryopreservation in terms of morphology and growth 
characteristics. The results revealed that the cells were positive for the expression of 
vimentin, and the specific fluorescence could be observed within the cytoplasm 
(Figure 2.2.1). The cells were negative for the expression of keratin. This supported 
their identity as fibroblasts.   
 
A 
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B 
C 
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Figure 2.2.1 Immunostaining and characterization of primary human Tenon’s capsule 
cultures. Cells were stained for nuclei (blue), vimentin (green), and keratin (red) under 40x 
magnification. Image A shows a complete image while B, C, and D show isolated images for 
nuclei, vimentin, and keratin stains respectively. Images displayed are representative of all images 
of samples taken. 
 
2.2.2 Corrosion of different coated magnesium alloys 
A total of 453 coated magnesium alloy disks were used in our experiments: 399 for 
assessment of metabolic activity, cytotoxicity, and cellular proliferation rates, and 54 
D 
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for western blot analysis (Table 2.2.2). The phenomenon of corrosion was observed in 
67 disks, accounting for 14.8%. The coating of DCPD and DCPD + SA had the same 
corrosion proportion (both 15.9%), while the HA coating had the lowest corrosion 
proportion (12.6%). The difference, however, was not statistically significant 
(chi-square test, χ2 = 0.876, P = 0.645).  
 
Table 2.2.2 Corrosion rate of different coated magnesium alloys (events). 
 DCPD DCPD+SA HA Total 
Corrosion 24 24 19 67 
No corrosion  127 127 132 386 
Total 151 151 151 453 
Proportion  15.9% 15.9% 12.6% 14.8% 
The difference was not statistically significant (chi-square test, χ2 = 0.876, P = 0.645). 
 
2.2.3 The corrosion susceptibility of different coatings from day 2 to day 
7 
A total of 324 samples were used for assessment of metabolic activity and 
cytotoxicity from day 2 to day 7. As shown in Table 2.2.3, corrosion of the HA 
coating was more frequently found during the last three days (8/10), while corrosion 
of the DCPD coating was more commonly seen during the first three days (6/9). The 
two-way ANOVA analysis revealed that the corrosion susceptibility of different 
coatings was not statistically different (Pcoating=0.729, Pday=0.903). 
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Table 2.2.3 The corrosion susceptibility of different coatings on different days (events/disks). 
 DCPD DCPD+SA HA 
Day 2 2/18 1/18 0/18 
Day 3 3/18 1/18 1/18 
Day 4 1/18 1/18 1/18 
Day 5 0/18 2/18 3/18 
Day 6 1/18 1/18 3/18 
Day7 2/18 1/18 2/18 
The difference was not statistically significant (two-way ANOVA, PCoating=0.729, PDay=0.903). 
 
2.3 Discussion 
Coatings increased the corrosion resistance of magnesium alloys 
The total corrosion rate was 14.8%, and the HA coating showed a relatively more 
stable property compared with DCPD and DCPD + SA. 
 
Mg alloys have unique properties, providing the mechanical benefits of a metal 
combined with the degradable and biological advantages of biomaterials 131. However, 
in spite of significant recent research, corrosion is a major challenge to successful 
implementation of Mg-based materials in the body. In addition, the wear resistance of 
Mg and Mg alloys is not very high. Therefore, a broad range of coating systems have 
been developed to overcome these weaknesses for numerous applications 132,133. 
 
   
２３ 
Recently, calcium phosphate-based coatings have attracted special interests for 
biomedical application as bone substitutes and orthopaedic materials 134, including 
DCPD, DCPD + SA, and HA. Particularly, the formation of a HA layer is similar to 
the mineral phase of bone 135-137，and more smoothly than other two coatings. In our 
experiments, the HA coating was more stable than DCPD or DCPD + SA. 
Interestingly, in the MTT and LDH assays, where disks were immersed in the culture 
medium for 7 days, most of the corrosion events of the HA-coated magnesium alloys 
occurred during the last three days, accounting for 80%. Therefore, we conclude that 
the HA coating has better corrosion resistance at the beginning of the cellular 
logarithmic phase. 
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Chapter 3 
Corrosive properties of coated magnesium alloys in simulated 
aqueous humor   
3.1 Background 
Due to their excellent bio-compatibility, magnesium alloys are being considered as 
promising implant materials. However, the poor corrosion resistance becomes a major 
obstacle to their widespread applications. Currently, the focus of bio-magnesium 
studies is on coatings or surface modification to slow the degradation rates of Mg 
alloys. If coated magnesium alloys are going to be used a biomaterial candidate for 
glaucoma drainage device, not only gradual degradation is needed to control the 
overall corrosion process, but also pH maintenance and control of ions released into 
the anterior chamber are also required to maintain a non-toxic concentration of each 
ions. These conditions very rapidly alter as a result of the corrosion process, with 
rapid changes in pH levels and metal ion concentrations, as well as presence of 
soluble corrosion products and hydrogen gas evolution. Thus, we need a complicated 
solution that considers the corrosion resistance, metal ion concentrations, pH and 
mechanical performance of coated magnesium alloy implants when immersed in the 
aqueous humor. It is essential to fully understand the long term corrosion engineering 
and potential biological interactions. Thus we invited our collaborators (National 
Engineering Research Center for Magnesium Alloys, Chongqing University, China) 
using balanced salt solution to test the variation of pH, sample’s weight, and ion 
concentrations. 
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3.2 Materials and methods 
3.2.1 Corrosion resistance test 
The corrosion resistance, ion release, sample weight change, and pH change were 
investigated by immersion of coated and uncoated magnesium alloy samples in 
balanced salt solution (BSS, Alcon, USA). The BSS components are shown in Table 
3.2.1. 
Four prepared samples were placed on a specially made PVC plastic stent and soaked 
in a 150ml containing balanced salt solution (BSS), and each sample was weighed 
before test. Each sample set 4 groups, each group of a specimen in a ground glass 
stoppered flask. And then remove flasks to a 37℃ 5% CO2 incubator(Shanghai 
Shengke 101) . 
 
3.2.1.1 The SEM morphologies 
The SEM morphologies were observed at 5 and 9d. The coated sample was covered 
with specific conductive liquid to allow it to conduct electricity. The pure maganism 
sample can be directly placed in the electron microscope. 
 
3.2.1.2 The pH test 
The pHs of three groups in each sample were measured at 1, 2, 5, 9, and 15d. The 
electrode was rinsed by BSS before test. The instrument of pH test was Shanghai Lida 
phs-3c. 
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3.2.1.3 Variation of weight 
3 discs of each sample were taken out respectively at 2, 5, 9, 15 and 21d. The discs 
were rinsed by deionized water and 100% ethanol, and then slowly dried the discs 
with cold wind. After weighed on an electronic scale, the discs continued to immerse 
in BSS.  
 
3.2.1.4 Variation of ion concentrations 
2ml different soaking solutions were extracted at 1, 5, and 9d, respectively, diluted 
two times, detection of magnesium, calcium, phosphorus content in solution, and 
compared with BSS solution. The result of these three ions content was removed the 
content of ions in the blank solution. The instrument used is inductively coupled 
plasma emission spectrometry (ICP-OES) 
 
Table 3.2.1 Components of aqueous humor and simulated aqueous humor. 
 Aqueous humor Balanced salt solution (Alcon) 
Na+ (mmol/L) 163 156 
K+ (mmol/L) 2.3-3.9 10.1 
Ca2+ (mmol/L) 1.8 3.3 
Mg2+ (mmol/L) 1.1 1.5 
Cl- (mmol/L) 132 129 
pH 7.38 7.4 
Osmotic pressure 
(mmHg) 
304 305 
 
3.3 Results 
3.3.1 Microstructure of different coatings 
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The SEM morphologies for different coatings are shown in Figure 3.3.1. After 
immersion for 9 days, the coating of DCPD and DCPD + SA was dissolved and 
flaked, with cracked surface. The HA coating was exfoliated from the matrix on day 5, 
but without any obvious changes on the surface of non-exfoliated areas.      
 
 
A B 
C D 
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Figure 3.3.1: SEM images of coated magnesium samples after immersion under different 
magnifications.  Image A and B shows the DCPD coated sample at 100x and1000x magnification. 
Image C and D shows the DCPD+SA coated sample at 100x and 500x magnification. Image E and F 
shows the HA coated sample at 500x and 2000x magnification. Graphs from National Engineering 
Research Center for Magnesium Alloys, Chongqing University, China  
 
 
3.3.2 pH variations of BSS   
As shown in Figure 3.3.2, the pH levels of all samples rapidly increased during the 
first two days. The pure magnesium group had higher pH levels compared with other 
groups, but after day 5, the pH levels of the pure magnesium group slightly declined. 
The pH levels of all coating groups gradually increased after day 2. The pH levels of 
the HA coating group was constantly higher than those of the DCPD and DCPD + SA 
groups. 
E F 
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Figure 3.3.2 Variation of BSS pH of coated and uncoated samples over time.  
The pHs of three groups in each sample were measured at 1, 2, 5, 9, and 15 days. The electrode was 
rinsed by BSS before each test. Graphs from National Engineering Research Center for 
Magnesium Alloys, Chongqing University, China  
 
 
3.3.3 Sample weight changes in BSS 
The changes of sample weight during the immersion test are shown in Figure 3.3.3. 
The sample weight was slightly reduced in the pure magnesium group and the HA 
coating group during the first 5 days, but gradually increased after day 5. The sample 
weight of the DCPD and DCPD + SA groups was dramatically reduced during the 
first 2 days, but gradually increased after day 2 in the DCPC + SA group. In the 
DCPC group, weight loss became slower from day 2 to day 5, but the sample weight 
began to increase after day 5. 
Day 
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Figure 3.3.3 Weight changes of coated and uncoated samples over time. 
Discs were taken out at 2, 5, 9, 15 and 21 days. The discs were rinsed by deionized water, 100% 
ethanol, air-dried and then weighed on an electronic scale. Graphs from National Engineering 
Research Center for Magnesium Alloys, Chongqing University, China  
  
 
3.3.4 Changes of ion concentrations during immersion test. 
As shown in Figure 3.3.4.a, the magnesium concentration of all groups gradually 
increased from day 1 to day 9. The magnesium concentration in the pure magnesium 
group was obviously higher than that of other groups.   
 
The calcium concentration of the DCPD and DCPD + SA groups was much higher 
than that of the HA group (Figure 3.3.4.b). The calcium concentration of all the 
coating groups rapidly increased on day 1, and then declined afterwards. The calcium 
concentration of the DCPD + SA group rocketed at the beginning, but rapidly dropped 
after day 1 and became lower than that of the DCPD group after day 5.  
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As for the changes of the phosphorus concentration (Figure 3.3.4.c), the DCPD and 
DCPD + SA groups showed a similar trend with that of calcium, i.e. rapid increase on 
day 1, and then gradual reduction afterwards. The DCPD group had a higher 
phosphorus concentration than that of the DCPD + SA group. Interestingly, the 
phosphorus concentration was not detectable in the HA group.  
 
 
(a) 
 
(b) 
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(c) 
Figure 3.3.4 Ion concentration changes during immersion test.  
(a), (b) and (c) illustrate the changes of magnesium, calcium and phosphorus concentrations 
during immersion test, respectively. 2ml different soaking solutions were extracted at 1, 5, and 9d, 
respectively, diluted two times, detection of magnesium, calcium, phosphorus content in solution. 
Graphs from National Engineering Research Center for Magnesium Alloys, Chongqing 
University, China  
   
 
3.4 Discussion  
3.4.1 Effect of coating on corrosion process 
BSS is an intraocular irrigating solution commonly used in ophthalmic surgeries to 
perfuse and support the anterior chamber to prevent its collapse during operation. Its 
properties, including pH value, ion concentrations and osmotic pressure, are generally 
similar to those of human aqueous humor. Thus, BSS was applied in the immersion 
test as simulated aqueous humor. 
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The pH level of BSS and aqueous humor is 7.4, which may corrode magnesium alloy, 
while the presence of chloride (Cl-) ions would aggravate the corrosion leading to 
dissolution of magnesium 138,139. The dissolution of magnesium consumes the 
hydrogen (H+) ions in the solution, resulting in a continuous rise in the pH of the 
solution 140. During the immersion test, the pure magnesium group had higher pH 
levels than other groups, indicating that coating could prevent dissolution of the 
matrix and protect against corrosion, thus delaying changes in the pH level. 
 
The samples is stable in the dry air is long-term and stable. In vitro experiment, by 
immersion in BSS for 21 days, the DCPD and DCPD+SA coated samples lost about 1% 
weight loss, HA and pure magnesium did not test to weightlessness. Weight loss of 
samples is caused by dissolution of coating and matrix. The surfaces of coatings have 
some small pores that causing the solution permeate into the matrix. Although the 
corrosion of coating and matrix almost occur at same time，but in the early stage, 
corrosion medium is slow and difficult to penetrate the coating. According to the pure 
magnesium disks almost did not lose any weight during the test, and thus it could be 
concluded that dissolution of the coating was the major contributor to weight loss. 
Similarly, the weight of the HA disks remained almost the same throughout the test, 
indicating that the coating of HA had better ability to protect against dissolution. 
Compared with the DCPD and DCPD + SA coated samples, the HA coated samples 
had lower weight loss rate because of the protective effect on the matrix. Additionally, 
the oxide layer of the original metal surface grows inwards and outwards at the same 
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time, and thus the weight change of samples consists of two parts: dissolution causing 
weight loss and deposition of magnesium hydroxide (Mg(OH)2) causing weight gain 
141. During the later stage of this test, magnesium hydroxide deposition might exceed 
dissolution, leading to increases in the sample weight．This explains why the weight 
of each group gradually increased after rapid decline. 
 
According to these results, our collaborators estimated that the pure magnesium in 
BSS solution can maintain the stability for more than 1 month and the coated 
magnesium alloys can maintain the stable state for longer periods. But vitro 
experiments had big difference compare to vivo experiments, because there is no 
bioactivity in vitro experiment. Therefore，the purpose of immersion corrosion test is 
screening for a promising coating for future research. 
 
3.4.2 Ion release of different samples during immersion test.  
Compared with the DCPD and DCPD + SA coated samples, the HA coated samples 
released fewer ions contained in the coating. This finding demonstrated that the 
coating of HA could prevent dissolution and corrosion of magnesium alloys in an 
effective and stable manner. Interestingly, DCPD is a precursor for the synthesis of 
HA 141,142; it can be dissolved in physiological environment and release calcium and 
phosphorus which form of HA with precipitation 143. This is why more calcium and 
phosphorus ions were released in the DCPD and DCPD + SA groups. However, the 
dissolution rate of the DCPD and DCPD + SA coating was higher than inducing the 
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formation of HA crystals.  
 
3.4.3 SEM morphologies of different coatings after immersion test 
According to the SEM photographs, the coating of DCPD and DCPD + SA was 
dissolved and flaked, with cracked surface observed on day 9. Although the HA 
coating was exfoliated from the matrix, no obvious changes were noted on the surface 
of non-exfoliated areas. Therefore, we speculate that the main problem of the HA 
coating is an increased risk of detachment from the matrix. If it can be improved to 
attach more closely with the matrix, we believe that this type of coating could 
effectively reduce the corrosion rate of magnesium alloys. 
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Chapter 4 
The effect of different coatings on metabolic activity and necrosis of 
HTCFs 
4.1 Background  
Various kinds of metal-based tissue implants have been developed since the 20th 
century. But they still have many defects that remain to be addressed. For instance, 
nickel-titanium alloy implants cause potential harm to the human body 144, because of 
the release of Ni+. The titanium has been widely used as a biocompatible surgical 
device. Despite the wide belief that it is inert, allergic reactions and stress shielding 
effects have been reported after implantation 145. 
 
Magnesium is the second most common cation in the intracellular fluid, also the 
fourth most common metallic ion in the body, mainly located in the cytoplasm. It 
participates in a series of metabolic processes in the body. In order for magnesium 
alloys to be developed as a tissue implantable material in the future, we not only need 
to solve the key adverse effect of corrosion in the human body, but also consider the 
cytotoxicity of coating and its effects on cellular metabolism. Therefore, it is very 
important to investigate the biocompatibility of differently coated magnesium alloys. 
 
In our previous experiments, differently coated magnesium alloy disks were used to 
treat cells for only 24 hours, but as a potential biomaterial for future glaucoma 
drainage devices, coated magnesium alloys would exist in the conjunctiva for a 
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relatively longer period of time, and thus it would be necessary to investigate the 
long-term effect of differently coated magnesium alloys on HTCFs.  
4.2 Materials and methods  
4.2.1 MTT assay 
The primary HTCFs were seeded on DCPD, DCPD + SA, and HA disks in a 24-well 
culture plate, 2 x 104 cells per well from Day 2 to Day 7. Glass disks were used as 
controls. The assay was performed according to the manufacturer's instructions. MTT 
(Sigma, USA) was added at the final concentration of about 450 ug/ml. MTT 
concentrations in the stock: 5 mg/mL for 1 mL cell culture medium, and 0.5 mL was 
added to each well. Cells were placed in a 37oC 5% CO2 incubator. After 3 hours, the 
supernatant was aspirated from culture wells. The precipitate in each well was 
resuspended by adding 0.5 mL dimethyl sulfoxide (DMSO, Sigma, USA) to solubilize 
formazan crystals. Subsequently, the solution was completely mixed, and 100 uL was 
removed from each well to 3 wells of a 96-well plate. Absorbances at 575 nm were 
determined using a microplate reader (Molecular Devices, Sunnyvale, CA). Control 
cells, which represented 100% metabolic activity, were used to normalize absorbances. 
At least 6 samples per group were measured in duplicate. 
 
4.2.2 Lactate dehydrogenase cytotoxicity(LDH) assay 
The supernatant of different groups were collected from Day 2 to Day 7. Glass was 
used as control. The collected supernatant was analysed using a LDH cytotoxicity kit 
(Roche, USA), and the assay was performed according to the manufacturer’s 
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instructions. The collected supernatant was centrifuged at 1000 x 10 min. Three 1.5 
mL tubes were labeled as 1, 2 and 3. Next, 7.5 uL LDH (Sigma, USA) solution was 
diluted with 992.5 uL PBS solution in tube 1, and then 100 uL solution was extracted 
from tube 1 to tube 2 which contained 900 uL PBS solution. Finally, 100 uL solution 
was extracted from tube 2 to tube 3 which also contained 900 uL PBS solution. To the 
final row standard lanes, 200 uL of the diluted LDH solution (0.5 U/mL) was added to 
2 wells of the 96-well plate. Using a multipipette with PBS, 100 uL PBS was placed 
into the other wells of the standard lanes. The standards were serially diluted so that 
each well had a final volume of 100 uL, and then each standard was mixed well. And 
no LDH was contained in the first row. The amount of the total reaction solution was 
determined and 100 uL reaction solutions was added to each well and allowed to 
incubate for 10-15 min at room temperature. Optical densities of the solutions were 
read at dual wavelength of 490/655 nm. Control cells, which represented 100% 
cytotoxicity, were used to normalize absorbances. At least 6 samples per group were 
measured in duplicate. 
 
4.2.3 Statistical analysis 
The MTT and LDH assay results were analyzed using two-way ANOVA test. 
Statistical significance was accepted at P < 0.05. All analyses were performed using 
SPSS 24.0 software. 
 
4.3 Results 
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4.3.1 Time and cellular metabolic activity curves 
The MTT assay was used to determine cellular metabolic activity. In the presence of 
viable cells, MTT was enzymatically reduced to the purple dye formazan. The 
multiple curves represented the variation of metabolic activities of HTCFs which 
were treated by different disks from day 1 to day 7 (Figure 4.3.1). The p value of 
different treatments was statistically significant (ptreatment < 0.001). The metabolic 
activity of the DCPD + SA group, which gradually declined from day 2 to day 7, was 
significantly lower compared with other groups. The HTCFs seeded on the titanium 
plates had the highest viability. The HA group showed a higher metabolic activity 
during the first two days, but the viability gradually decreased and became lower than 
that of the DCPD group since day 4. The P value of time was not statistically 
significant (ptime = 0.195), indicating that time had no obvious influence on the 
metabolic activity of HTCFs.  
 
Figure 4.3.1 Cellular metabolic activity of different samples. 
MTT results from HTCFs treated with different coated magnesium alloys. The multiple curves 
represent the variation of metabolic activities of HTCFs which were treated by different disks from day 
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1 to day 7. MTT was added at a final concentration of 450 ug/ml, and 0.5 mL was added to each well. 
Cells were placed in a 37oC 5% CO2 incubator. After 3 hours, the supernatant was aspirated from 
culture wells. The precipitate in each well was resuspended by adding 0.5 mL dimethyl sulfoxide 
(DMSO, Sigma, USA) to solubilize formazan crystals. Data was analyzed using two-way ANOVA test. 
The source of statistical significance was determined by applying Tukey test (SPSS 24). ***ptreatment < 
0.001, ptime= 0.195; N = 6. 
  
4.3.2 Time and cytotoxicity curves 
The LDH assay was utilized to examine the cytotoxicity of coatings or necrosis of 
HTCFs seeded on different disks. Liberated nicotinamide adenine dinucleotide, 
formed from LDH’s conversion of lactate into pyruvate, subsequently reduced a 
tetrazolium dye into formazan, which could be detected using a spectrophotometer. 
The P value of treatments was statistically significant (ptreatment < 0.001). The HA 
group had the lowest cytotoxicity, which was statistically different compared with 
other groups. The cytotoxicity of the DCPD + SA group was higher than that of the 
HA and DCPD groups, but similar to that of the titanium (p = 0.468) and glass (p = 
0.976) groups. The p value of time was not statistically significant (ptime = 0.260). 
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Figure 4.3.2 Time and cytotoxicity curves of different samples. 
The supernatant of different groups were collected from Day 2 to Day 7. Glass was used as control. 
The collected supernatant was analysed using a LDH cytotoxicity kit (Roche, USA), and the assay was 
performed according to the manufacturer’s instructions. Data was analyzed using two-way ANOVA 
test. The source of statistically significance was determined by applying Tukey test (SPSS 24). 
***ptreatment < 0.001, ptime = 0.260; N = 6. 
 
4.4 Discussion  
4.4.1 The influence of time  
A prior study reported that the logarithmic phase of HTCFs was from 48 hours to 7 
days 146. Therefore, in order to examine the relationship between the HTCFs’ 
metabolic activity and time, and to investigate the variation of cytotoxicity during this 
period, we performed the MTT and LDH assays of treated HTCFs from day 2 to day 
7. The results revealed that no statistically significant difference was observed in 
metabolic activity or necrosis at different time points during the logarithmic phase 
(p=0.195, p=0.260, respectively). Based on these findings, the factor of time was not a 
major contributor to reduced metabolic activity and increased cytotoxicity in this in 
vitro experiment. Thus, those two curves could basically describe the influence of 
different treatments on HTCFs during the logarithmic phase. These results were used 
to as a basis for the design of future experiments to assess cellular function, such as 
BrdU, Western blotting and RT-PCR.    
  
4.4.2 Biocompatibility of coated magnesium alloys 
The purpose of this study was to evaluate the biocompatibility of coated magnesium 
alloys which might be promising materials for novel drainage devices. Lorenz A et 
al.147 reported that cell death on untreated pure magnesium samples occurred within 1 
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day, whereas surface passivation could enable survival of a number of cells on Mg. 
However, cell densities were found to be reduced on Mg samples even with prior 
passivation treatments, compared with glass substrates used as a reference. Cell death 
was thought to be related to the ongoing corrosion of Mg in cell culture medium, 
leading to a pH increase. A recent study indicated that cell culture tests could not 
provide enough volume to compensate for the high concentration of Mg2+ ions or the 
alkaline pH shift in solution, and hence might not be appropriate for testing resorbable 
materials 148. Although coatings could reduce Mg2+ release from pure magnesium 
matrix and prevent pH increase, the coatings might influence the viability of cells and 
their cytotoxicity might lead to necrosis of HTCFs.  
 
In the MTT and LDH assays, the p value of different treatments was statistically 
significant (p < 0.001). The DCPD + SA group had the lowest metabolic activity but 
higher cytotoxicity than the other two coatings. The coatings of both HA and DCPD 
had lower cytotoxicity than titanium and glass. 
 
HA is attributed to the compositions of bioactive and bioresorbable ceramics or 
substances close to it in composition which forms HA crystals by the reaction with the 
organism at the implant-biomedium interface 149. Synthetic HA is a complete 
chemical and crystalochemical analog of bone mineral. This chemical similarity with 
bone accounts for their osteoconductive potential and excellent biocompatibility 135,136. 
In fact, HA, as a biological material, has been used in ophthalmological clinical 
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practice for a long time, such as HA orbital implants. Because of its excellent 
biocompatibility, HA orbital implant exposure rarely causes rejection after 
implantation 
 
In our experiments, the HA coating also showed excellent biocompatibility which had 
higher metabolic activity and the lowest cytotoxicity compared with other coatings. 
Therefore, we believe that HA is a very promising type of coating for glaucoma 
drainage devices. 
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Chapter 5 
Anti-proliferative potential of coated magnesium alloys on HTCFs 
5.1 Background  
Nowadays, glaucoma drainage implants have become increasingly useful in surgical 
management of glaucoma, especially for refractory glaucoma 150, including 
neovascular glaucoma, secondary glaucoma and remnant glaucoma. Glaucoma 
drainage devices are designed to divert aqueous humor from the anterior chamber to 
an external reservoir 151. However, postoperative scarring is a major risk factor 
affecting surgical success rate. Moreover, glaucoma drainage device encapsulation 
may result in loss of the external reservoir function, leading to IOP increase and 
surgical failure. 
 
It has been shown that inflammatory reaction is a main risk factor leading to 
postoperative scarring 152. Foreign bodies inevitably induce rejection and activate 
some specific proteins which will trigger a localized inflammatory response and 
provide a short-term structural support. The inflammatory phase is characterized by 
the activation of the innate immune system and the release of inflammatory cytokines. 
At present, the commonly used materials for glaucoma drainage devices are titanium 
and silicone which are not biodegradable materials. Although they have good 
biological compatibility, their presence as permanent foreign body under the 
conjunctiva, stimulates fibroblast proliferation and glaucoma drainage device 
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encapsulation 153.  
  
Magnesium alloy possesses many advantageous properties such as non-toxicity, 
absorbable and high biological compatibility. However, it has been reported that the 
corrosion of magnesium could increase pH levels and lead to cell death 147. In this 
research we took advantage of the ability to modulate these corrosive properties by 
the employing the use of coating materials. It was our goal to determine if we could 
use the more controlled corrosive properties to modulate the behavior of fibroblastic 
cells.   
5.2 Materials and methods 
5.2.1 BrdU assay 
The proliferation of HTCFs was monitored by 5-bromo-2-deoxyuridine 
(BrdU)-incorporation into cellular DNA using the Cell Proliferation BrdU assay kit 
(Merck KGaA, Darmstadt, Germany) as recommended by the manufacturer. Cell 
suspension in medium containing 10% FBS was placed on a 24-well culture plate 
(BD Falcon, BD Biosciences, Broendby, Denmark), 0.5 mL per well at a 
concentration of 0.5 x 104 cells⁄mL and was incubated for 48 hours. Cellular DNA 
was labeled for 24 hours using BrdU labeling reagent. After ﬁxation, the cells were 
incubated with anti-BrdU antibody for 60 min at room temperature. Then the cells 
were washed, peroxidase goat antimouse IgG conjugate was added and the cells were 
incubated for 30 min. After addition of substrate solution, the plate was read using a 
spectrophotometer microplate reader with dual wavelength set at 450/595 nm. The 
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glass group was used as control. At least 6 samples per group were measured in 
duplicate. 
 
5.2.2 Protein extraction and Western blotting analysis  
Western blotting was performed on HTCFs samples derived from glaucoma patients. 
After treatment, the cells were rinsed with ice-cold PBS twice, and the total cell 
proteins were extracted using RIPA lysis buffer (20 mM Tris, 150 mM NaCl, 1 Mm 
EDTA, 1% Triton X-100) containing phosphatase inhibitors and protease inhibitors. 
Protein concentrations were determined by micro BCA protein assay (Thermo 
Scientific, CA). Following the manufacturer’s instructions, 10% SDS-polyacrylamide 
gel and 5% stocking gel were prepared and placed inside the electophorator 
containing running buffer. And then, 6 uL marker (Invitrogen, Thermo Fisher 
Scientific, CA) was loaded on the left lane, followed by 10 mg of each sample. The 
gel was run at 120 V for stocking gel and at 100 V for 10% SDS-polyacrylamide gel. 
Subsequently, the gel was transferred to a polyvinylidene diﬂuoride (PVDF) 
membrane (Invitrogen, Thermo Fisher Scientific, CA) using a Bio-Rad gel-blotting 
apparatus (Invitrogen, Thermo Fisher Scientific, CA). Membranes were blocked in 5% 
milk in Tris-Buffered Saline Tween (TBST; 10 mM Tris HCl, 150 mM NaCl, 0.1% 
Tween 20) for 1 hour, and probed with antibodies against α-smooth muscle actin 
(α-SMA, Abcam, USA) at a dilution of 1:1000, then incubated with primary antibody 
overnight at 4oC and with a peroxidase-conjugated secondary antibody for 1 hour at 
room temperature. After these incubations, membranes were washed in TBST for 30 
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minutes. Western blotting detection kit (WesternBright Quantum, USA) was used to 
visualize for enhanced chemiluminescence (Chemi genius2, Syngene, USA) and 
exposure. To ensure equal protein loading, nitrocellulose membranes were stripped 
with stripping buffer (Restore, Thermo Scientific, CA) and reprobed with 
anti-glyceraldehyde-3phosphate dehydrogenase (GAPDH) antibody at a dilution of 
1:2000 (Santa Cruz, Biotechnology, USA). At least 6 samples per group were 
measured in duplicate. 
 
5.3 Results 
5.3.1 Cell proliferation study 
The BrdU cell proliferation assay was used to determine the proliferation of HTCFs. 
The HTCFs seeded on the titanium disks showed a greater proliferative ability; the 
cell proliferation rate of the titanium group was significantly higher than that of the 
glass group (p=0.049). The proliferation rate of the DCPD + SA group was 
significantly lower compared with the glass group (p=0.047); that of the DCPD group 
was almost the same as the glass group; and the HA group had a slightly higher 
proliferation rate than that of the DCPD group. In addition, all types of coated 
magnesium alloys showed a lower proliferation rate compared with the titanium 
group. 
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Figure 5.3.1 Relative proliferation rate of HTCFs. 
The proliferation of HTCFs was monitored by 5-bromo-2-deoxyuridine (BrdU)-incorporation into 
cellular DNA using the Cell Proliferation BrdU assay kit as recommended by the manufacturer. Data 
was analyzed using one-way ANOVA test (SPSS 24). *p < 0.001 compared with glass; N = 6. 
 
5.3.2 Western blotting analysis  
The protein of α-SMA is a marker of myofibrobalsts which cause fibroblast 
proliferation and wound scarring 154. Normalized to GAPDH expression，the glass 
group had the highest α-SMA expression. The α-SMA expression level of the titanium 
group was slightly lower than that of the glass group. All types of coated magnesium 
alloys had lower α-SMA expression levels than that of the titanium group or the glass 
group. The DCPD group and the DCPD + SA group had similar α-SMA expressions. 
The HA group had the lowest α-SMA expression level, which was significantly lower 
than that of the glass group (p=0.037) and the titanium group (0.001). 
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Figure 5.3.2 α-SMA protein expression normalized to GAPDH expression. 
Western blotting was performed on HTCFs samples derived from glaucoma patients. The total cell 
proteins were extracted using RIPA lysis buffer containing phosphatase inhibitors and protease 
inhibitors. Protein concentrations were determined by micro BCA protein assay (Thermo Scientific, 
CA). The test performed following the manufacturer’s instruction. Data was analyzed using one-way 
ANOVA test (SPSS 24). **p=0.001; N=6. 
 
5.4 Discussion  
5.4.1 Coated magnesium alloys attenuate HTCFs proliferation  
According to the BrdU cell proliferation assay, coated magnesium alloys were 
associated with lower proliferation rates of HTCFs as compared with titanium. In the 
BrdU assay, the same number of cells was loaded to each well at the beginning, but 
due to the lower cytotoxicity and better metabolic activity of cells seeded on the 
titanium disks, more cells grew and proliferated on the titanium disks after 48 hours. 
The DCPD + SA coating had higher cytotoxicity and lower metabolic activity than 
other coatings, and thereby a lower proliferation rate was observed in this group. Even 
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if in the LDH assay the DCPD + SA group showed almost the same necrosis of 
HTCFs with that of the titanium and glass groups, we still speculated that this type of 
coating might cause apoptosis of HTCFs. Unfortunately, we have tried many assays to 
assess apoptosis in our experiments, such as Elisa and caspase-3, but due to the 
reagent reaction with coated magnesium alloy disks, the effect of each sample on the 
apoptosis of HTCFs remained unclear, and further studies are needed to address this 
issue. 
 
5.4.2 HA coating inhibits α-SMA expression  
HA is chemically similar to bone, and has excellent biocompatibility 135,136. Actually, 
HA as a biological material has been used to fabricate orbital implants for a long time. 
And HA orbital implants have been widely used in clinical practice with excellent 
performance, and no obvious adverse effects have been reported 155. As the data of 
α-SMA expression had been normalized to that of GAPDH, we believed that the 
results of western blotting were more reliable and convincing. The expression of 
α-SMA proteins is a marker of myofibroblasts, which reflects the number and 
proliferation of myofibroblasts 156. It also is an important marker to estimate scar 
formation or surgical prognosis. In our experiment, the α-SMA expression levels 
decreased in all the coated magnesium alloy groups. Furthermore, in comparison with 
glass and titanium, the HA coating significantly reduced the expression of α-SMA. 
These findings indicate that HA coated magnesium alloy which has better corrosion 
resistance, lower cytotoxicity and excellent biocompatibility could inhibit α-SMA 
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protein expression and prevent scarring. Therefore, HA coating may be considered a 
very promising biodegradable material for the next generation glaucoma drainage 
devices.  
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Chapter 6 
Conclusion 
6.1 Summary of results  
As described in Chapter Two, human tenon’s capsule tissue samples were obtained 
from 32 glaucoma patients. Primary cell culture and subculture were performed to 
acquire adequate number of HTCFs for the following experiments. 
Immunofluorescence staining performed for vimentin and keratin verified the purity 
and identity of the HTCFcultures. Coated magnesium alloy and titanium samples 
were fabricated and cut into disks with 14.5 mm in diameter and 1 mm in thickness, 
specific for 24 well culture plate. A total of 453 coated magnesium alloy disks were 
used in our experiments. The phenomenon of corrosion was observed in 67 disks, 
accounting for 14.8%. The coatings of DCPD and DCPD + SA had the same 
corrosion rate (both 15.9%), while the HA coating had the lowest corrosion rate 
(12.6%). These differences were not statistically significant as determined by the 
chi-square test.  Most of the corrosion events of the HA coated samples were found 
during the last three days (8/10), whereas the DCPD coated samples were more prone 
to corrosion during the first four days (6/9). Based on two-way ANOVA analysis, 
however, the differences were not statistically significant. 
 
In Chapter Three, long-term changes in sample weight, pH levels, and ion 
concentrations, were determined by immersion of coated magnesium alloys in BSS 
solution which had similar components of human aqueous humor. The SEM 
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morphologies revealed that after immersion for 9 days, the DCPD and DCPD + SA 
coatings were dissolved and flaked, with cracked surface. The HA coating was 
exfoliated from the matrix after 5 days, but without any obvious changes on the 
surface of non-exfoliated areas. This finding indicated that the main problem of the 
HA coating is an increased risk of detachment from the matrix. This coating showed 
the greatest promise to effectively reduce the corrosion rate of magnesium alloys if 
further development can be done to improve the attachment to the matrix. The pH 
levels rapidly increased in all groups during the first two days. The pure magnesium 
group had higher pH levels than other groups. The dissolution of magnesium 
consumes the H+ in the solution, resulting in a continuous rise in the pH of the 
solution. Thus, this result revealed that coatings could prevent pH increase because of 
inhibited dissolution and corrosion of the matrix. The DCPD and DCPD + SA groups 
lost much more weight than the HA and pure magnesium groups, indicating that the 
coating dissolution was the major reason leading to sample weight loss during the 
immersion test. Additionally, the magnesium concentration in the pure magnesium 
group was obviously higher than that of the other three coated groups, which 
demonstrated that coatings could reduce the release of magnesium ions from the pure 
magnesium matrix. Compared with the DCPD and DCPD + SA coatings, the HA 
coating released fewer calcium ions and no phosphorus ions were detected, indicating 
that the HA coating was associated with a significantly lower risk of dissolution and 
corrosion. 
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In Chapter Four, we examined the biocompatibility of differently coated magnesium 
alloys. We used MTT assay to evaluate the metabolic activity of HTCFs and LDH 
assay to determine the cytotoxicity of coated magnesium alloys; the glass and 
titanium disks were used as controls. Meanwhile, we utilized these in vitro 
experiments to investigate the variation of metabolic activity and necrosis of HTCFs 
during the logarithmic phase. The results of MTT assay showed that the P value of 
treatment was statistically significant. The metabolic activity of HTCFs in the DCPD 
+ SA group was the lowest, while the HTCFs seeded on the titanium disks displayed 
the highest viability. The results of LDH assay also showed that the P value of 
treatment was statistically significant. The HA group had the lowest cytotoxicity, 
while the DCPD + SA group had higher cytotoxicity than other coatings, but 
comparable to the titanium and glass groups in terms of necrosis. Notably, both of the 
two assays indicated that the P value of time was not statistically significant, 
indicating that time had no obvious influence on the metabolic activity and necrosis of 
HTCFs from day 2 to day 7. 
 
In Chapter Five, we attempted to utilize some of the corrosive properties of coated 
magnesium alloys to evaluate their potential anti-scarring ability. The BrdU assay was 
used to assess cellular proliferation, and the cells seeded on the titanium disks showed 
a greater proliferative ability. Compared with the glass group, the proliferation rate of 
the DCPD + SA group was significantly lower, and all types of coated magnesium 
alloys showed lower proliferation rates. These results demonstrated that coated 
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magnesium alloys have a better potential to inhibit cellular proliferation than titanium. 
In western blotting analysis, we chose α-SMA proteins to examine the growth of 
myofibrobalsts on different disks, because the expression of α-SMA is a marker of 
myofibrobalsts. Normalized to GAPDH expression, the α-SMA expression was 
inhibited by coated magnesium alloys. The result of ANOVA showed that the p value 
was statistically significant difference. Compared with the glass and titanium groups, 
the expression level of α-SMA was significantly reduced in cells seeded on the HA 
disks. 
 
6.2 Limitations of the study 
Our investigation consisted of an in vitro cell culture model designed to investigate 
the biocompatibility and anti-proliferative potential of differently coated magnesium 
alloys as novel drainage device materials for glaucoma surgeries. As mentioned in 
Chapters 2 and 3, the coated magnesium alloys tested still likely have unacceptable 
corrosion rate as implant materials. In our experiments, the average corrosion 
percentage was 14.8%, and even the most stable type - HA coating - still had a 
corrosion proportion of 12.6%. Although the incidence of corrosion is much lower 
than that of pure magnesium, it would have to be improved before this material could 
be considered for in vivo surgical implantation. Actually, the coating decreased 
corrosion rate of magnesium，but cannot completely prevent the occurrence of 
corrosion, because the coating will gradually lose their integrity and degraded. In fact, 
we do not expect that the coating could completely prevent the magnesium corrosion, 
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because we expect this is a kind of biodegradable material, if the coating completely 
prevent corrosion, the material becomes unbiodegradable. Based upon these 
experiments, the HA coating showed the greatest promise, especially if the material 
could be modified to be more closely adhere to the magnesium alloy. In the 
immersion test, we selected BSS as simulated aqueous humor to investigate the 
longer-term properties of coated magnesium alloys. It would have been informative to 
also assess hydrogen emission, which would likely have an influence on the tissue 
properties at the surgical site. Further studies are needed to examine the volume of 
hydrogen emission based on the size of glaucoma drainage device. 
 
This is an in vitro study, and, as such, it is not representative of an in vivo biological 
environment. True biocompatibility profiles in animal studies would be required as a 
next step towards the development of these materials as a surgical device in the 
human body. Although this is a historical challenge, it is also well accepted that these 
types of experiments are necessary to develop the foundation for future in vivo 
experimentation, the latter that require significant resources.  In Chapter 4，we found 
that magnesium alloys could reduce the metabolic activity of HTCFs and are less 
likely to cause necrosis of these cells. Although attempted by ELISA, it was not 
possible to assess apoptosis by this technique due to the effects of the materials on the 
assay.   Future experiments that employ alternative methods for determining 
apoptosis should be considered.   The proliferation rate of the DCPD + SA group 
was significantly lower than other groups, but its cytotoxicity was almost the same as 
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that of glass and titanium in the LDH assay. Therefore, we infer that the DCPD + SA 
coating may accelerate cell apoptosis. More studies are required to further investigate 
the apoptosis of HTCFs seeded on coated magnesium alloy disks. 
 
In Chapter 5, we performed the BrdU assay and detected the expression of α-SMA 
proteins to examine the anti-proliferative potential of differently coated magnesium 
alloys. In future studies, it would be useful to assess the expression of collagen-1 to 
further explore the potential of coated magnesium alloys in inhibiting protein 
expressions. RT-PCR may also be performed to determine whether coated magnesium 
alloys could suppress mRNA synthesis. 
 
6.3 Future directions 
In this section, future directions are presented to address the identified limitations and 
expand upon the findings of the current study. Continued study of the corrosion 
resistance of magnesium alloys would be useful, especially if correlated to the effect 
on the apoptosis of HTCFs, and their anti-proliferative potentials. Prototypes of 
coated magnesium alloy-based glaucoma drainage device should be designed.  
Based upon these designs, the size of the devices would permit determination of the 
daily volume of hydrogen release, which experiments to determine the safe and 
acceptable ranges..  
 
Upon completion of the in vitro phase of these experiments, future animal studies 
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would be designed.  Implantation of the coated magnesium alloy-based glaucoma 
drainage device into the eyes of New Zealand rabbits would allow determination of 
the effects on the tissue and organ. Parameters such as scar formation and 
encapsulation, as well as the postoperative adverse events related to the corrosion 
would be useful to obtain. 
 
Anti-scarring will continue to be a focus of our future studies, and the release of 
different ions from coatings will be assessed in a comprehensive fashion. For example, 
matrix metalloproteinases proteins are associated with scar formation and regulated 
by calcium ions 157. Based on the findings of the immersion test, it was found that 
calcium ions were released from the coatings when they came in contact with body 
fluids. Therefore, we speculate that the increased extracellular calcium concentration 
may influence the expression of matrix metalloproteinases and scar formation, which 
needs to be validated in further studies. 
 
6.4 Concluding remarks 
Magnesium alloy is a novel biodegradable material which possesses many 
advantageous properties which may render it useful as a surgical adjunctive device.  
These properties include: non-toxicity, high strength, light weight, and high biological 
compatibility. Complications related to its corrosive properties caused it to lose 
interest as a potential implantable device in the middle of the 20th century.   
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More recent advancements in the area of coating technology have allowed the 
synthesis of novel coated magnesium alloys, which have shown significant promise as 
effective biodegradable materials. In this thesis the corrosive response of a selected 
group of coated magnesium alloys was reported. Although the corrosion rates were 
still relatively high, the ability of the coatings to differentially modulate these rates, 
and reduce them in comparison to pure magnesium, was demonstrated.  
 
Scarring caused by fibroblast proliferation is a major risk factor leading to glaucoma 
surgery failure. In the process of degradation of coated magnesium alloys, different 
ions are released, changing the pH of extracellular environment and thereby affecting 
the proliferation of cells. In this study, cellular proliferation when treated by 
differently coated magnesium alloys was examined, and the potential anti-scarring 
properties were also investigated. The results showed that, when compared with 
titanium, coated magnesium alloys could effectively inhibit the proliferation of 
HTCFs and reduce the expression of myofibroblast specific antibodies.  
 
6.5 Conclusions of full text 
1. Coatings are able to effect the corrosive properties of magnesium.  
2. HA was most resistant to corrosion. 
3. No significant difference was found in metabolic activity or necrosis at different 
times during the logarithmic phase of HTCFs. 
4. DCPD+SA demonstrated a stronger ability to reduce metabolic activity while its 
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cytotoxic profile was the same as titanium and glass. 
5. In comparison to titanium, coated magnesium alloys attenuated HTCFs 
proliferation. 
6. Coated magnesium alloys reduced the expression of α-SMA. 
7. The expression of α-SMA was significantly decreased in cells exposed to the HA 
coated magnesium. 
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